BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 29671861)

  • 1. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction.
    Gasecka A; Nieuwland R; Budnik M; Dignat-George F; Eyileten C; Harrison P; Huczek Z; Kapłon-Cieślicka A; Lacroix R; Opolski G; Pluta K; van der Pol E; Postuła M; Leroyer A; Siljander P; Sturk A; Filipiak KJ
    Platelets; 2020; 31(1):26-32. PubMed ID: 30585111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
    Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
    Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
    Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
    Vaduganathan M; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
    [No Abstract]   [Full Text] [Related]  

  • 9. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
    Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
    Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
    Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
    J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
    Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
    Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition by P2Y
    Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
    Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.
    Jin J; Quinton TM; Zhang J; Rittenhouse SE; Kunapuli SP
    Blood; 2002 Jan; 99(1):193-8. PubMed ID: 11756171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
    Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.